These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 27016222)

  • 1. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
    Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
    Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
    Hirshfield KM; Tolkunov D; Zhong H; Ali SM; Stein MN; Murphy S; Vig H; Vazquez A; Glod J; Moss RA; Belyi V; Chan CS; Chen S; Goodell L; Foran D; Yelensky R; Palma NA; Sun JX; Miller VA; Stephens PJ; Ross JS; Kaufman H; Poplin E; Mehnert J; Tan AR; Bertino JR; Aisner J; DiPaola RS; Rodriguez-Rodriguez L; Ganesan S
    Oncologist; 2016 Nov; 21(11):1315-1325. PubMed ID: 27566247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
    Charo LM; Eskander RN; Sicklick J; Kim KH; Lim HJ; Okamura R; Lee S; Subramanian R; Schwab R; Shatsky R; Plaxe S; Kato S; Kurzrock R
    JCO Precis Oncol; 2022 Jan; 6():e2000508. PubMed ID: 35005995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
    Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
    Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiling of gynecologic cancers and implications for clinical practice.
    Prendergast EN; Elvin JA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):18-25. PubMed ID: 27984344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
    Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
    Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
    Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
    Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
    J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
    Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
    Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
    Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
    Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
    Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
    Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
    VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
    J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
    Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
    JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
    Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
    Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.